Intra-articular Injection Of Botulinum Toxin Research Articles

Intra-Articular Injection of Botulinum Toxin for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.

The purpose of the present paper was to review the available evidence on intra-articular botulinum toxin (BTX) injection in the treatment of knee osteoarthritis and to compare it to other conservative treatment options. A systematic review of the literature was performed on the PubMed, Scopus, Cochrane Library, Web of Science, Pedro and Research Gate databases with the following inclusion criteria: (1) randomized controlled trials (RCTs), (2) written in the English language, and (3) published on indexed journals in the last 20 years (2001-2021) dealing with the use of BTX intra-articular injection for the treatment of knee OA. The risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs. Nine studies involving 811 patients in total were included. Patients in the control groups received different treatments: conventional physiotherapy, hyaluronic acid injection or prolotherapy or a combination thereof in 5 studies, steroid infiltrative therapy (triamcinolone) in 1 study, placebo in 2, and local anesthetic treatment in 1 study. Looking at the quality of the available literature, two of the included studies reached "Good quality" standard, three were ranked as "Fair", and the rest were considered "Poor". No major complications or serious adverse events were reported following intra-articular BTX, which provided encouraging pain relief, improved motor function, and quality of life. Based on the available data, no clear indication emerged from the comparison of BTX with other established treatments for knee OA. The analysis of the available RCTs on BTX intra-articular injection for the treatment of knee OA revealed modest methodological quality. However, based on the data retrieved, botulinum toxin has been proven to provide good short-term outcomes, especially in patients with pain sensitization, by modulating neurotransmitter release, peripheral nociceptive transduction, and acting on the control of chronic pain from central sensitization.

Efficacy of Intra Articular Botulinum Toxin Injection in Sickle Cell Patients’ Joints

Efficacy of Intra Articular Botulinum Toxin Injection in Sickle Cell Patients’ Joints

Ultrasound guided intra-articular botulinum toxin injection for treatment of the osteoarthritic knee pain: expert opinion.

Osteoarthritis is the most common form of arthritis and cause of joint pain and disability [1]. The prevalence, burden and socioeconomic impact of osteoarthritis of the knee is considerable and growing [2]. Knee pain is the most cardinal symptom of the osteoarthritic knee and is associated with a high degree of impaired function and daily activities [3]. Intra-articular injection provides a safe and cost effective control of knee pain with improvement of function and activities of daily living [4]. Ultrasound guidance improves the accuracy of the intra-articular injection in knee joint and clinical outcomes and lowers health care costs [5]. Botulinum toxin targets many neuropeptides leading to reduction of pain, peripheral sensitization and in turn reduction of the central sensitization. Also, botulinum toxin plays an anti-inflammatory role by reduction of the neurogenic inflammation [6]. The following table summarizes how to use botulinum toxin in clinical practice according to authors experience. However, further large-scale multicenter randomized controlled trials are needed to confirm effectiveness and determine the exact position of this intervention in the therapeutic armamentarium for the osteoarthritic knee pain.

Effect of intra-articular Botulinum toxin injections on temporo-mandibular joint pain

Temporo-mandibular joint dysfunction can be painful and disabling. In some cases, it is refractory to classical treatment. Intra-articular Botulinum toxin injections have been shown to have an anti-inflammatory and analgesic effect. The aim of this study was to evaluate the effectiveness of such injections on severe, refractory temporo-mandibular joint pain. This was a retrospective study. Patients were included if they still had joint pain≥5 on a Visual Analogue Scale following completion of all other treatments. A complete treatment protocol (including physiotherapy, tongue splints, intra muscular injections of Botulinum toxin and injections of hyaluronic acid, excluding surgery) having being done before the injection of 30 Botox* units (Botulinum toxin A), the treatment being considered clinically successful if the Visual Analogue Scale decreases by at least 2 points. Seventy-seven patients were included. Sixty-six percent of patients have a significant reduction in pain at 1 month which lasted at least until 3 months. Mouth opening and quality of life also improved. Moreover, no complications were reported. Further randomized, controlled studies are needed to confirm the results, however this study suggests intra-articular injection of Botulinum toxin is a safe and effective treatment for severe, refractory temporo-mandibular joint pain, avoiding surgery.

Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: protocol for a randomised trial (RHIBOT)

IntroductionRecent studies have suggested that intra-articular injection of botulinum toxin A (BTA) may have analgesic effects in degenerative joint diseases. We aim to assess the efficacy of intra-articular injection of...

Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model

Currently, administration of Botulinum toxin Type A (BoNT/A) to treat arthritic pain has promising efficacy in clinical research. However, the mechanisms underlying anti-neurogenic inflammation mediated by BoNT/A remains unclear. The aim of this study was to demonstrate the effectiveness in macro and micro levels and to explore the causal mechanism of BoNT/A.Wistar rats (n = 60) were injected with 50ul complete Freund's adjuvant (CFA) in the left ankle joint capsule to establish a model of chronic monoarthritis. Pain behaviour (Evoked pain assessment) and infrared thermal imaging testing were performed at the macroscopic level to assess the effectiveness of analgesia and anti-inflammation. Western blotting and immunofluorescence staining were used at the microscopic level in an attempt to determine the mechanisms of anti-nociceptive or anti-inflammatory effects of BoNT/A. Additionally, hematoxylin-eosin staining was also used to visualise the cartilage and the synovial degenerative conditions of arthritis. By comparing the outcome of the evoked pain test and immunofluorescence staining, there was a significant improvement in BoNT/A compared with the normal saline (NS) injected control group. In addition, thermal variations showed that the temperature of ipsilateral ankle joint increased between 1 and 2 weeks following injection of CFA, but decreased after 3 weeks (still above the contralateral side). However, the temperature showed no difference between the BoNT/A group and NS group after treatment. The expression of IL-1β or TNF-α in the ankle synovial tissue was significantly decreased in the BoNT/A group compared to the NS group (p < 0.05). Based on the HE assessment, cartilage degeneration and infiltration of inflammatory cells in the BoNT/A group was alleviated compared to the NS group after treatment. In conclusion, we proposed the hypothesis that intra-articular BoNT/A administration does play an important role in anti-neurogenic inflammation. The possible mechanisms might be that BoNT/A prevents the release of nociceptive nerve peptides at the injection site and then suppresses the expression of inflammatory cytokines.

Intra-articular injections of botulinum toxin a for refractory joint pain: a systematic review and meta-analysis

Objective: To assess the benefit of intra-articular injection of Botulinum toxin A (BoNT-A) for chronic refractory joint pain regardless of joint or pathology. Data sources: The search was performed on Ovid MEDLINE(R) In-Process and Other Non-Indexed Citations, Ovid MEDLINE(R), Ovid EMBASE, Web of Science, and Scopus inception through Week 12, 2016. Trial selection: Clinical randomized controlled trials that evaluated BoNT-A intra-articular injection in patients with refractory joint pain were included. Data extraction: Two independent reviewers conducted data extraction. Results: A total of 6 out of 284 records were included. The analysis indicated that a statistically significant decreased pain score was found in BoNT-A therapy group than control group with WMD=1.10 (95% CI: 0.35 to 1.85; P<0.001; I2=95%); WMD=0.7 (95% CI: 0.09 to 1.32; P=0.02; I2=0%) at week 4, and 8 after injection, respectively. WOMAC score was also significant decreased in BoNT-A therapy group than control group with WMD=4.71 (95% CI: 2.76 to 6.67; P<0.001; I2=0%); WMD=3.67 (95% CI: 1.08 to 6.26; P=0.006; I2=27%) at week 4 and12 after injection, respectively. There was no difference in adverse event between BoNT-A therapy group and control group with OR=1.25 (95% CI: 0.88 to 1.78; P=0.47; I2=0%). Conclusion: As compared with conventional therapy, BoNT-A intra-articular injection have beneficial effects with improved pain score and WOMAC score in adult patients with refractory joint pain.

Usefulness of intra-articular botulinum toxin injections. A systematic review

Botulinum toxin is a proven and widely used treatment for numerous conditions characterized by excessive muscular contractions. Recent studies have assessed the analgesic effect of botulinum toxin in joint pain and started to unravel its mechanisms. Literature-search-methodologyWe searched the international literature via the Medline database using the term “intraarticular botulinum toxin injection” combined with any of the following terms: “knee”, “ankle”, “shoulder”, “osteoarthritis”, “adhesive capsulitis of the shoulder”. ResultsOf 16 selected articles about intraarticular botulinum toxin injections, 7 were randomized controlled trials done in patients with osteoarthritis, adhesive capsulitis of the shoulder, or chronic pain after joint replacement surgery. Proof of anti-nociceptive effects was obtained in some of these indications and the safety and tolerance profile was satisfactory. The studies are heterogeneous. The comparator was usually a glucocorticoid or a placebo; a single study used hyaluronic acid. Pain intensity was the primary outcome measure. Discussion-conclusionThe number of randomized trials and sample sizes are too small to provide a satisfactory level of scientific evidence or statistical power. Unanswered issues include the effective dosage and the optimal dilution and injection modalities of botulinum toxin.

Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle

Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle

Treatment of frozen shoulder with intra-articular injection of botulinum toxin in shoulder joints

Frozen shoulder, or adhesive capsulitis, is a disease of chronic inflammation and fibrosis involving the shoulder joints. The disease is challenging in clinical practice due to painful treatment course, with disease evolution usually lasting weeks or even months, causing significant discomfort and functional loss. Botulinum toxin (BTX) has been discovered to possess abilities in pain management at various clinical diseases. The actual mechanism is still under investigation, and involves inhibition of neurotransmitter release. In addition, BTX is also found to retard process of fibrosis, which is also a key issue in pathogenesis of frozen shoulder. Therefore, we hypothesize that intra-articular injection of BTX can be an effective alternative for treatment of frozen shoulder.

Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases

We report the use of intra-articular Botulinum toxin A in two RA patients with persistently painful monoarthritis in ankle/feet joints. Both patients had monarticular pain despite a good response of all other joints to a combination therapy that included anti-tumor necrosis factor therapy. Both patients had failed intra-articular corticosteroid injections and declined surgical options. After a single, “off-label”, intra-articular injection of Botulinum toxin A into the right ankle (100 unit) and left first metatarsophalangeal joint (25 unit), respectively, pain and function improved significantly (≥40%) in both patients. Durable response with improvement of pain and function lasting 15–18 months was noted (follow-up continuing). Ankle joint swelling resolved by 15 months and MTP joint swelling by one month. Intra-articular BoNT/A may be an additional therapeutic option in RA patients with persistent monoarthritis. A randomized study is underway to confirm these findings.